GLP-1 (glucagon-like peptide 1) medications are revolutionizing weight loss and diabetes care, but behind the hype lies a growing web of regulatory gaps, telehealth expansion and online pharmacy risks. This episode unpacks the opportunities -- and dangers -- shaping the future of these life-changing drugs.

Featuring: Scott Roth, Chief Executive Officer, LegitScript

Gerard Olsen, Director of Research, LegitScript

In today’s episode, we'll cover…

To learn more about GLP-1 medications from all angles, check out our Pharma Life Sciences, Patient Engagement and Healthcare Payers sites.

To watch video clips from the conversation, subscribe to our YouTube channel, @HealthcareStrategies.

References:

Metabolic bariatric surgery in the GLP-1 era

Risks of online semaglutide without prescription

FDA updates on GLP-1 compounding policies